RxDoctor Payments Data

Yekaterina Karpitskaya, MD

Orthopaedic Surgery · Biloxi, MSNPI 1932223542

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (39.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Arthrex at 47.0% of the total. Reporting peaked in 2022 at $5,149 and has fallen 89.4% since, to $548 in 2025.

$9,199in general payments, 2019–2025

Across 86 payments — averaging $106.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$4K
  • ALON Medical Technology$2K
  • Johnson & Johnson$621
  • Sanara Medtech Inc.$582
  • Smith+Nephew$362
  • Bioventus LLC$256
  • plus $614 from 13 others

What the payments were for

  • Speaking & faculty fees$2062%
  • Travel & lodging$2,16123%
  • Food & beverage$3,21835%
  • Education$3,61439%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,199 in reported general payments places this provider in the 65th percentile of 170 orthopaedic surgery providers in Mississippi.

See all orthopaedic surgery providers in Mississippi

Medicare billing

Part B allowed, 2024
$232,257
Medicare patients
423
Services billed
9,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$6,454
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen155$1,470
Celecoxib52$1,028
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen125$1,013
Meloxicam357$808
Tizanidine Hcl43$251
Methylprednisolone38$238
Methocarbamol11$213
Gabapentin42$189
Ondansetron OdtOndansetron27$187
Ibuprofen20$171
Tramadol Hcl61$151
Scopolamine12$133
Cyclobenzaprine Hcl43$131
Mupirocin17$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$6,45415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 170 orthopaedic surgery providers in Mississippi.

Other orthopaedic surgery in Biloxi

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →